TITLE

Journal Club

AUTHOR(S)
Oliver, Juan; Schlöndorff, Detlef
PUB. DATE
April 2007
SOURCE
Kidney International;Apr2007, Vol. 71 Issue 7, p606
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents various articles submitted including "Hydronephrosis and renal abnormalities in DLGH1 mice," and "hypoxia-inducible factors is the critical factor regulating erythropoietin and erythropoiesis in the adult," both by Juan Oliver and another on immunoglobulin A nephropathy-like disease.
ACCESSION #
24486801

 

Related Articles

  • F. Clinical Renal Pharmacology and Therapeutics.  // Kidney;May/Jun2005, Vol. 14 Issue 3, p142 

    Presents abstracts of several studies on clinical renal pharmacology and therapeutics. "Nephrolithiasis and Hydronephrosis in an HIV-infected Man Receiving Tenofovir," by P. Cicconi, M. Bongiovanni, S. Melzi, et al, published in the 2004 issue of "International Journal of Antimicrobial Agents";...

  • Leukemia kidney infiltration can cause secondary polycythemia by activating hypoxia-inducible factor (HIF) pathway. Osumi, Tomoo; Awazu, Midori; Fujimura, Eriko; Yamazaki, Fumito; Hashiguchi, Akinori; Shimada, Hiroyuki // European Journal of Pediatrics;Jun2013, Vol. 172 Issue 6, p829 

    Secondary polycythemia with increased production of erythropoietin (EPO) is known to occur in kidney diseases such as hydronephrosis and cystic disease, but the mechanism remains unclear. We report an 18-year-old female with isolated renal relapse of acute lymphoblastic leukemia accompanied by...

  • Hydronephrosis, poor renal function can spell endopyelotomy failure. Watson, Fiona // Urology Times;Mar97, Vol. 25 Issue 3, p24 

    Discusses the effect of high-grade hydronephrosis and poor renal function in endopyelotomy failure. Success rate in patients with marked and moderate hydronephrosis; Success rate in patients with poor renal function; Importance of crossing vessels in endopyelotomy failure; Chances of failure of...

  • Organ distribution of erythropoietin messenger RNA in normal and uremic rats. Tan, Chorch C.; Eckardt, Kai-Uwe; Ratcliffe, Peter J. // Kidney International;Jul1991, Vol. 40 Issue 1, p69 

    We used RNAase protection assays to measure low levels of erythropoietin messenger RNA (EPO mRNA) in the organs of unstimulated rats, and to compare basal and stimulated levels of EPO mRNA in the kidneys and extrarenal organs of rats rendered uremic by subtotal nephrectomy, with pair-fed...

  • Anemia management and chronic renal failure progression. Rossert, Jerome; Froissart, Marc; Jacquot, Christian // Kidney International Supplement;Dec2005, Issue 99, pS76 

    Analysis of the biologic effects of erythropoietin and pathophysiology of chronic kidney diseases (CKD) suggests that treatment with erythropoiesis-stimulating agents (ESA) could slow the progression of CKD. By decreasing hypoxia and oxidative stress, it could prevent the development of...

  • Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects. Flamme, Ingo; Oehme, Felix; Ellinghaus, Peter; Jeske, Mario; Keldenich, Jörg; Thuss, Uwe // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    Oxygen sensing by hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) is the dominant regulatory mechanism of erythropoietin (EPO) expression. In chronic kidney disease (CKD), impaired EPO expression causes anemia, which can be treated by supplementation with recombinant human EPO (rhEPO)....

  • In This Issue.  // Kidney International;Aug2007, Vol. 72 Issue 4, p383 

    The article discusses various reports published within the issue, including one about the capability of statins in reducing morbidity from diabetic nephropathy and another about the beneficial effects of erythropoietin on a variety fo ischemic conditions.

  • Erythropoeitin dose variation in different facilities in different countries and its relationship to drug resistance. Greenwood, Roger N.; Ronco, Claudio; Gastaldon, Fiorella; Brendolan, Alessandra; Homel, Peter; Usvyat, Len; Bruno, Lenore; Carter, Mary; Levin, Nathan W. // Kidney International Supplement;Nov2003, Issue 87, p78 

    Erythropoeitin dose variation in different facilities in different countries and its relationship to drug resistance. The correction of anemia using erythropoeitin (EPO) is accorded high priority in the management of patients undergoing hemodialysis (HD). Target hemoglobin (Hb) levels have been...

  • Is the anemia of CKD always due to erythropoietin deficiency? Garcia, Jennifer L. // Veterinary Medicine;Aug2011, Vol. 106 Issue 8, p384 

    The article provides an answer to a question on the cause of the anemia of chronic kidney disease (CKD) due to erythropoietin deficiency.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics